3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
62
Carcinoma, Non-Small-Cell Lung
45
Triple Negative Breast Neoplasms
24
Ovarian Neoplasms
20
Fallopian Tube Neoplasms
17
Neoplasm Metastasis
16
Lung Neoplasms
16
Endometrial Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Stomach Neoplasms
12
Esophageal Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Neoplasms
9
Esophageal Squamous Cell Carcinoma
8
Colorectal Neoplasms
7
Inflammatory Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma
6
Uterine Cervical Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Melanoma
4
Carcinoma, Transitional Cell
4
Carcinoma, Squamous Cell
4
Adenocarcinoma Of Esophagus
4
Urinary Bladder Neoplasms
3
Peritoneal Neoplasms
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Lung Diseases
3
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Paclitaxel
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled